Evidence map›Paper›PMID 39971318›Full record

ArticleEndocrine journal2025

Assessing the potential of high-mobility group AT-hook 2 immunohistochemical staining as a prognostic marker of metastatic recurrence in follicular thyroid cancer: a retrospective cohort study.

Yuka Ito, Junko Sakumoto, Hideki Hirabayashi, Shinichi Haruna, Wataru Konno, Itsuo Nakajima, Kazuyuki Ishida, Yasuo Haruyama, Toshimi Sairenchi, Eijun Nishihara and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuka ItoDepartment of Genetic Diagnosis and Laboratory Medicine, Dokkyo Medical University, Tochigi 321-0293, Japan.ORCID http://orcid.org/0009-0006-4780-426X
Junko SakumotoDepartment of Genetic Diagnosis and Laboratory Medicine, Dokkyo Medical University, Tochigi 321-0293, Japan.
Hideki HirabayashiDepartment of Otorhinolaryngology, Head and Neck Surgery, Dokkyo Medical University, Tochigi 321-0293, Japan.
Shinichi HarunaDepartment of Otorhinolaryngology, Head and Neck Surgery, Dokkyo Medical University, Tochigi 321-0293, Japan.
Wataru KonnoDepartment of Otorhinolaryngology, Head and Neck Surgery, Dokkyo Medical University, Tochigi 321-0293, Japan.
Itsuo NakajimaDepartment of Otorhinolaryngology, Head and Neck Surgery, Dokkyo Medical University, Tochigi 321-0293, Japan.
Kazuyuki IshidaDepartment of Diagnostic Pathology, Dokkyo Medical University, Tochigi 321-0293, Japan.ORCID http://orcid.org/0000-0002-2804-4588
Yasuo HaruyamaDepartment of Public Health, Dokkyo Medical University, Tochigi 321-0293, Japan.ORCID http://orcid.org/0000-0001-6865-5159
Toshimi SairenchiMedical Science of Nursing, Dokkyo Medical University School of Nursing, Tochigi 321-0293, Japan.ORCID http://orcid.org/0000-0001-8896-6501
Eijun NishiharaKuma Hospital, Hyogo 650-0011, Japan.ORCID http://orcid.org/0000-0003-1786-0077
Shuji FukataKuma Hospital, Hyogo 650-0011, Japan.
Akira HishinumaHishinuma Clinic, Kanagawa 239-0841, Japan.
Takahiko KogaiDepartment of Genetic Diagnosis and Laboratory Medicine, Dokkyo Medical University, Tochigi 321-0293, Japan.ORCID http://orcid.org/0000-0002-2413-2564

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-mobility group AT-hook 2 (HMGA2) is a nuclear protein involved in the differentiation and proliferation of epithelial-derived tumors and also considered to be involved in the growth and differentiation of various malignant tumors, including thyroid cancer. Immunohistochemistry (IHC) for HMGA2 has been reported to show diffuse positivity in several follicular thyroid carcinoma (FTC) cases. This study aimed to investigate whether positive immunohistochemical staining for HMGA2 in primary tumors can be used to predict the prognosis and detect prognostic factors in malignant thyroid tumors associated with metastatic recurrence in FTC. Formalin-fixed, paraffin-embedded (FFPE) resected specimens used for the IHC for HMGA2. The association of positive HMGA2 staining with metastasis and recurrence, along with the potential of HMGA2 as a prognostic marker of metastatic recurrence, was statistically determined. HMGA2 staining was positive in most malignant tissues, whereas benign tissues were unstained. HMGA2 staining of the marginal and invasive regions was observed in FTC tissues. The association of HMGA2 staining with metastasis and recurrence was significant (p = 0.018). Kaplan-Meier curves showed an association of negative HMGA2 staining with metastasis and disease-free survival (p = 0.090). Tumor size (>4 cm) and wide invasion were also significant factors (p = 0.043, p < 0.001). The risk ratio without HMGA2 was significantly reduced by 30% compared to that with HMGA2. In primary tumors, positive HMGA2 staining can be used to predict prognosis in malignant thyroid tumors associated with metastatic recurrence in FTC and negative HMGA2 staining may indicate longer disease-free survival after surgery.

Indexed as

Adenocarcinoma, FollicularBiomarkers, TumorHMGA2 ProteinNeoplasm Recurrence, LocalThyroid NeoplasmsAdultAgedDisease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorHMGA2 ProteinHMGA2 protein, humanFollicular thyroid carcinoma (FTC)High-mobility group AT-hook 2 (HMGA2)Immunohistochemistry (IHC)Metastatic recurrencePrognosis

Identifiers

PMID39971318
PMCPMC12086272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.